OMM and Jingtian advise Peijia Medical on its $302 million IPO

O’Melveny & Myers and Jingtian & Gongcheng have advised Chinese medical device company Peijia Medical on its $302 million IPO on the HKEX, with Herbert Smith Freehills and Commerce & Finance Law Offices representing the underwriters.

Established in early 2012, Peijia Medical is a leading domestic player in the Chinese transcatheter valve therapy medical device and neuro-interventional medical device market, focusing on China's high-growth interventional medical device market. Peijia Medical has established a collaborative platform integrating R&D, manufacturing and commercialisation capabilities, and has a comprehensive product portfolio.

The Jingtian & Gongcheng team was led by Yusheng (Jerry) Ye.